Paul E. Freiman

Paul E. Freiman discloses dealings in 3 companies, chiefly Penwest Pharmaceuticals Co, Neurobiological Technologies Inc /CA/ and Neopharm Inc. Between 3 January 2006 and 3 September 2009, the trades on record add up to 69 filings.

On the open market, the record shows 1 purchase worth €6,748 and 14 sales worth €383k. The net balance comes to €376k on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 37 share grants and 8 option exercises. In 2009 alone, the filings show no purchases and 6 sales.

The record was last updated on 16 September 2009 with an open-market sale (€5,698) in Penwest Pharmaceuticals Co. The most recent open-market purchase was published on 5 December 2007, 6,898 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.